Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The OxfoRd Asthma attaCk risk ScaLE (ORACLE)
We had the great pleasure to meet with Dr. Ian Pavord (University of Oxford, Oxford, UK) and Dr. Simon Couillard (University of Oxford, Oxford, UK and University of Sherbrooke, Sherbrooke, Canada) to learn about the OxfoRd Asthma attaCk risk ScaLE (ORACLE), a proof-of-concept scale to predict asthma attacks. You can view the prototype Oxford Asthma Attack Risk ScaLE (ORACLE) here.
The abstract ‘A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE).‘ was presented at ATS 2021 International Conference, 14-19 May, 2021.
- What is known about the factors associated with increased annualised asthma attacks and what questions remain unanswered? (0:31)
- What were the aims and design of the prototype OxfoRd Asthma attaCk risk ScaLE (ORACLE) scale? (5:31)
Disclosures: In the last 5 years Ian Pavord has received speaker’s honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva. Simon Couillard has received a non-restricted research grant from Sanofi Genzyme for investigator-initiated type-2 innovation research; speaker honoraria from Sanofi-Regeneron and AstraZeneca; all outside the submitted work.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ATS 2021 (Virtual).
Share this Video
Related Videos In Asthma
Barbara Yawn, CHEST 2022: The role of respiratory specialists in herpes zoster vaccination
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. We caught up with Dr. Barbara Yawn (University of Minnesota, […]
Barbara Yawn, CHEST 2022: Herpes zoster vaccination in people with asthma or chronic obstructive pulmonary disease
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. touchRESPIRATORY were delighted to speak with Dr. Barbara Yawn (University […]
Cristiano Caruso, ERS 2022: 2 Year Findings from the REALITI-A Study of Mepolizumab in Severe Asthma
REALITI-A was an international, prospective, observational cohort study, investigating the real-world corticosteroid-sparing effect of mepolizumab in severe asthma. touchRESPIRATORY caught up with Dr. Cristiano Caruso (Columbus Hospital, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy) to discuss the aims, design, eligibility criteria and the 2 year findings from REALITI-A. The abstract ‘International, prospective study of mepolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!